Search - tctmd.com

Displaying 1 - 20 of 137

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2026

Caitlin E. Cox

February 02, 2026

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Opinion CV Team Dispatch

September 2025 Dispatch for the CV Team

L.A. McKeown

September 30, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

WHF Stresses the Importance of Polypills in Global Fight Against CVD

Yael L. Maxwell

September 09, 2025

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

Todd Neale

July 24, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Lp(a) Genetics Differ Between Populations but Have Similar Clinical Impact

Yael L. Maxwell

May 05, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Caitlin E. Cox

November 21, 2024

News Daily News

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Michael O'Riordan

November 13, 2024

News Daily News

Statins Are Cost-effective in the Elderly

Michael O'Riordan

September 11, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Caitlin E. Cox

August 31, 2024

News Daily News

ApoB Can Be High, Risky for ASCVD Even When LDL’s Normal

Yael L. Maxwell

June 17, 2024

News Daily News

Excess ApoB Linked to Increased MI, ASCVD Risk in Adults

Michael O'Riordan

June 04, 2024

News

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Michael O'Riordan

May 30, 2024

News Daily News

Statins Effective For Primary Prevention in Old and Very Old

Michael O'Riordan

May 29, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

Advertisement

TCTMD’s Top 10 Most Popular Stories for January 2026

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

September 2025 Dispatch for the CV Team

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

WHF Stresses the Importance of Polypills in Global Fight Against CVD

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Lp(a) Genetics Differ Between Populations but Have Similar Clinical Impact

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Top General Cardiology and Prevention News of 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Statins Are Cost-effective in the Elderly

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

ApoB Can Be High, Risky for ASCVD Even When LDL’s Normal

Excess ApoB Linked to Increased MI, ASCVD Risk in Adults

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Statins Effective For Primary Prevention in Old and Very Old

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content